Lead Product(s) : Birtamimab,Bortezomib,Cyclophosphamide
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Jefferies
Deal Size : Undisclosed
Deal Type : Public Offering
Prothena Announces Proposed Public Offering of Ordinary Shares
Details : Birtamimab, formerly known as NEOD001, is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
December 13, 2022
Lead Product(s) : Birtamimab,Bortezomib,Cyclophosphamide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Jefferies
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Birtamimab,Bortezomib,Cyclophosphamide
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Birtamimab is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Birtamimab,Bortezomib,Cyclophosphamide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable